UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 74

Sortiert nach

Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial

The lancet oncology, 2018-01, Vol.19 (1), p.51-64

2018

Volltextzugriff (PDF)

Do proton pump inhibitors modulate the efficacy of anti-PD-1/PD-L1 therapy? A retrospective study

Journal of oncology pharmacy practice, 2019-04, Vol.25 (3), p.762-764

2019

Volltextzugriff (PDF)

Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis

Journal for immunotherapy of cancer, 2020-10, Vol.8 (2), p.e001246

2020

Volltextzugriff (PDF)

Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancer

Cancer chemotherapy and pharmacology, 2021-05, Vol.87 (5), p.689-700

2021

Volltextzugriff (PDF)

Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC)

Investigational new drugs, 2021-02, Vol.39 (1), p.182-192

2021

Volltextzugriff (PDF)

A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic Cancer

Targeted oncology, 2021-09, Vol.16 (5), p.569-589

2021

Volltextzugriff (PDF)

Comparing the rate of immunotherapy treatment change due to toxicity by sex

Cancer reports, 2024-02, Vol.7 (2), p.e1932-n/a

2024

Volltextzugriff (PDF)

Neoadjuvant chemotherapy in the setting of locally advanced olfactory neuroblastoma with intracranial extension

Rare tumors, 2011-03, Vol.3 (1), p.e1-3

2011

Volltextzugriff (PDF)

The impact of BMI on the response to immunotherapy in lung cancer

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e21003-e21003

2022

Volltextzugriff (PDF)

Factors Affecting Natural Killer Cell Recovery after Autologous Stem Cell Transplantation in Multiple Myeloma

Blood, 2021-11, Vol.138 (Supplement 1), p.4895-4895

2021

Volltextzugriff (PDF)

A longitudinal study assessing the impact of ongoing COVID-19 pandemic among hematology-oncology trainees

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.11033-11033

2022

Volltextzugriff (PDF)

Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial

The lancet oncology, 2019-11, Vol.20 (11), p.1544-1555

2019

Volltextzugriff (PDF)

Prognostic impact of natural killer cell recovery on minimal residual disease after autologous stem cell transplantation in multiple myeloma

Transplant immunology, 2022-04, Vol.71, p.101544-101544, Article 101544

2022

Volltextzugriff (PDF)

Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study

Advances in therapy, 2021-01, Vol.38 (1), p.350-365

2021

Volltextzugriff (PDF)

Pegilodecakin as monotherapy or in combination with anti‐PD‐1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study

International journal of cancer, 2021-07, Vol.149 (2), p.403-408

2021

Volltextzugriff (PDF)

PD-L1, brain metastases, and survival among patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e21655-e21655

2020

Volltextzugriff (PDF)

A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors

Investigational new drugs, 2019-06, Vol.37 (3), p.461-472

2019

Volltextzugriff (PDF)

Long-Term Survival With Nanoliposomal Irinotecan in Pancreatic Cancer

Pancreas, 2020-10, Vol.49 (9), p.e95

2020

Volltextzugriff (PDF)

A Phase Ib Dose-Escalation Study of LCL161 Plus Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies

The oncologist (Dayton, Ohio), 2023-07, Vol.28 (7), p.640-e559

2023

Volltextzugriff (PDF)

Non-comparative, open-label, international, multicenter phase I/II study of nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with recurrent/metastatic merkel cell carcinoma (MCC) (CheckMate 358)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.9506-9506

2023

Volltextzugriff (PDF)

Ezabenlimab (BI 754091), an anti-PD-1 antibody, in patients with advanced solid tumours

Cancer Immunology, Immunotherapy : CII, 2024-03, Vol.73 (5), p.89-89, Article 89

2024

Volltextzugriff (PDF)

Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors

Clinical cancer research, 2020-12, Vol.26 (23), p.6196-6203

2020

Volltextzugriff (PDF)

Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA -Mutant Cancers

Clinical cancer research, 2021-01, Vol.27 (2), p.447-459

2021

Volltextzugriff (PDF)

Harnessing the PD-1 Pathway in Myelodysplastic Syndrome

American journal of therapeutics, 2018-11, Vol.25 (6), p.e711

2018

Volltextzugriff (PDF)

1 – 25 von 74

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(73)
Mit Volltextzugriff
(70)

Publikationsform

Artikel
(73)
Berichte
(1)

Sprache

Englisch
(74)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(26)
Science & Technology
(26)
Humans
(21)
Oncology
(21)
Female
(14)
Male
(12)
Middle Aged
(11)
Tumors
(10)
Aged
(9)
Adult
(7)
Immunotherapy
(7)
Medicine
(7)
Medicine & Public Health
(7)
Pharmacology & Pharmacy
(7)
Toxicity
(7)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(6)
Cancer
(6)
Monoclonal Antibodies
(6)
Patients
(6)
Pd-1 Protein
(6)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial

Do proton pump inhibitors modulate the efficacy of anti-PD-1/PD-L1 therapy? A retrospective study

Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis

Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancer

Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC)

A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic Cancer

Comparing the rate of immunotherapy treatment change due to toxicity by sex

Neoadjuvant chemotherapy in the setting of locally advanced olfactory neuroblastoma with intracranial extension

Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade

The impact of BMI on the response to immunotherapy in lung cancer

Factors Affecting Natural Killer Cell Recovery after Autologous Stem Cell Transplantation in Multiple Myeloma

A longitudinal study assessing the impact of ongoing COVID-19 pandemic among hematology-oncology trainees

Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial

Prognostic impact of natural killer cell recovery on minimal residual disease after autologous stem cell transplantation in multiple myeloma

Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study

Pegilodecakin as monotherapy or in combination with anti‐PD‐1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study

PD-L1, brain metastases, and survival among patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors

A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors

Long-Term Survival With Nanoliposomal Irinotecan in Pancreatic Cancer

A Phase Ib Dose-Escalation Study of LCL161 Plus Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies

Non-comparative, open-label, international, multicenter phase I/II study of nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with recurrent/metastatic merkel cell carcinoma (MCC) (CheckMate 358)

Ezabenlimab (BI 754091), an anti-PD-1 antibody, in patients with advanced solid tumours

Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors

Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA -Mutant Cancers

Harnessing the PD-1 Pathway in Myelodysplastic Syndrome

Suchergebnisse filtern